Abstract. Human Cripto-1, a membrane-bound protein, plays an important role during early embryogenesis and has oncogenic properties, including cell transformation and enhancement of invasion. Cripto-1 is up-regulated in various malignant tissues and premalignant lesions. However, Cripto-1 expression in intraductal papillary mucinous neoplasms (IPMNs) has yet to be reported. This study aimed to investigate Cripto-1 expression in IPMNs and evaluate the expression patterns according to the histological grade or phenotypic subclassification. Cripto-1 expression was evaluated by immunohistochemistry using 37 IPMN tissue samples and real-time RT-PCR analysis of seven frozen samples. Cripto-1 was up-regulated in 59.5% of IPMNs. Cripto-1 was positively stained in 3 of 4 (75%) adenomas, 12 of 19 (63.2%) borderline neoplasms, 5 of 11 (45.5%) non-invasive carcinomas and 2 of 3 (66.7%) invasive carcinomas. There was no correlation between Cripto-1 overexpression and the histological grade (P>0.05). Cripto-1 expression was significantly increased in pancreatobiliary-(4/5, 80%) and gastric-type (13/19, 68.4.2%) IPMNs compared with those of the intestinal type (2/10, 20%; P<0.01). Cripto-1 mRNA expression was higher in gastricand pancreatobiliary-type IPMNs than in intestinal ones, supporting the immunohistochemical results. It is concluded that Cripto-1 overexpression is involved in the tumorigenesis of gastric-and pancreatobiliary-type IPMNs.
Introduction
The intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a unique pancreatic neoplasm involving main and/ or branch pancreatic ducts (1) . IPMN is characterized by the intraductal papillary proliferation of neoplastic mucinous epithelium and cystic dilatation of the pancreatic ducts (2, 3) . The spectrum of IPMNs includes benign and malignant lesions, which are identified as adenomas, borderline tumors and carcinomas. Of note to us was the more favorable prognosis of IPMNs compared to pancreatic ductal adenocarcinomas, especially their tumorigenesis (3) .
IPMNs have been classified into four subtypes based on histological phenotypes and the expression of mucin core protein (MUC) (4) . The gastric-type IPMN resembles gastric foveloar epithelium with a negative expression of MUC1 and MUC2. The intestinal-type IPMN consists of cells resembling intestinal villous neoplasms with tall columnar epithelial cells and shows a positive expression of MUC2. The pancreatobiliary type of IPMN shows cholangiopapillary neoplasms with a positive expression of MUC1. The oncocytic type of IPMN consists of cells with abundant and intensely eosinophilic cytoplasm and shows a focal positive expression of MUC1. Although the IPMN subtypes show distinct phenotypic and histological differences, the carcinogenic differences between subtypes have been poorly studied.
Human Cripto-1 is a member of the epidermal growth factor-Cripto-FRL-Criptic (EGF-CFC) family, which includes mouse Cripto-1, cryptic Xenopus FRL-1, zebrafish one-eyedpinhead (oep) and chick Cripto (5). Cripto-1 is a membranebound protein, anchored by glycosylphosphatidylinositol, and acts as a cell surface co-receptor (5-7). Cripto-1 functions as a soluble protein after cleavage of the glycosylphosphatidylinositol linkage (8) . EGF-CFC proteins play an important role in the formation of the mesoderm and endoderm during gastrulation and are essential for cell movements that correctly orient the embryo along the anterior/posterior and left/right axes in embryogenesis (5, 9) . Cripto-1 also functions as an (10) (11) (12) . It is highly expressed in various malignancies, including stomach, colon, breast, lung and pancreatic cancer (13) (14) (15) (16) , and overexpressed in premalignant lesions and early stage gastric and colon cancer, suggesting its activation plays an important role in the early stages of carcinogenesis (17, 18) .
The present study aimed to analyze the Cripto-1 expression in surgical IPMN specimens using immunohistochemical staining and real-time RT-PCR, to clarify its relationship with the histological grade and phenotypic subtype, and to elucidate the association between Cripto-1 expression and IPMN tumorigenesis. Immunohistochemical staining. The primary antibodies used were: anti-Cripto-1 (89646, monoclonal, R&D systems, Minneapolis, USA; 1:200 dilution), anti-MUC1 (Ma552, monoclonal, Novocastra Laboratories, Newcastle upon Tyne, UK; 1:200 dilution) and anti-MUC2 (H-300, polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200 dilution). Formalin-fixed, paraffin-embedded tissues were cut into 4 μm sections, deparaffinized with xylene and rehydrated with graded alcohol. Endogenous peroxidase activity was blocked by incubating slides at room temperature for 15 min in methanol containing 3% hydrogen peroxide. Microwave antigen retrieval was performed in citrate buffer (0.01 M, pH 6.0) for 10 min. To reduce non-specific staining, slides were incubated with 10% normal donkey serum solution for 30 min. Blocked sections were incubated in primary antibody overnight at 4˚C and stained with a streptavidin-biotin peroxidase kit according to the manufacturer's protocol. Slides were developed by incubating with 3-amino-9-ethyl carbazole and counterstained with hematoxylin. Breast cancer tissue was used as a positive control. A negative control was created by applying secondary antibody without primary antibody.
Materials and methods

Patients
Evaluation of immunohistochemical staining of Cripto-1.
The immunohistochemical staining of Cripto-1 was evaluated within the area showing the highest degree of dysplasia in each IPMN. Samples were evaluated by two pathologists who did not have any knowledge of patient clinical information. We scored samples according to the percentage of Cripto-1 positive tumor cells as: <10%, 0; 10-25%, 1+; 25-50%, 2+ and >50%, 3+. Scores of 2+ and 3+ were regarded as being indicative of the positive expression of Cripto-1.
Real-time RT-PCR.
For analysis by real-time RT-PCR, three normal pancreas specimens from ampullary tumors and seven IPMN specimens were obtained. Total RNA was extracted using an RNeasy mini kit (Qiagen, Hilden, Germany) and cDNA was synthesized using the Superscript II system (Invitrogen, Carlsbad, CA, USA) as described previously (19) . Quantification of Cripto-1 mRNA was conducted using the SYBR-Green RT-PCR kit (Invitrogen) and ABI PRISM 7300 sequence detector (Applied BioSystems, Foster City, CA) according to the manufacturers' instructions. In brief, the total volume of the reaction mixture was 25 μl, containing 12.5 μl of SYBR-Green qRCR Supermix (Invitrogen), 5 pmol of sense and antisense primer and 5 μl of cDNA. The reaction was run online at 50˚C for 2 min and 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 sec and 60˚C for 60 sec. After real-time PCR, the temperature was increased from 60 to 95˚C at a rate of 2˚C/min to construct a melting curve. The results were analyzed with the melting curve analysis software (Dissociation Curve 1.0; Applied BioSystems) provided with the ABI PRISM 7300 sequence detector. The expression of Cripto-1 mRNA was normalized to that of the reference gene, RPL13A (20) . Relative quantification of Cripto-1 mRNA within the samples examined was performed using the comparative Ct method (ΔCt sample -ΔCt calibrator = ΔΔCt; relative quantity = 2 -ΔΔCt ) (21) . The primers used were: Cripto-1 forward: 5'-TGGCCCGCTTCTCTTACAGTG-3' and reverse: 5'-CCCCGAGATGGACGAGCAAAT-3'; and RPL13A forward: 5'-GGCCCAGCAGTACCTGTTTA-3' and reverse: 5'-AGATGGCGGAGGTGCAG-3'.
Statistical analysis. Fisher's exact test was used to compare Cripto-1 expression with the histological grades and subtypes. The Cripto-1 expression scores were compared with the histological grades using Spearman's correlation and subtypes using Pearson's methods. The IPMN subtypes and Cripto-1 expression were compared with clinicopathological parameters using Fisher's exact and Mann-Whitney U-tests.
Results
Clinicopathological features and phenotypic subclassification. The clinicopathological findings from the 37 cases are summarized in Table I . Of 37 cases, 4 (10.8%) were classified as adenomas, 19 (51.4%) as borderline neoplasms, 11 (29.7%) as non-invasive carcinomas and 3 (8.1%) as invasive carcinomas (Table I ). According to the phenotypic subclassification, 19 (51.4%) were subclassified as gastric, 10 (27%) as intestinal, 5 (13.5%) as pancreatobiliary, 1 (2.7%) as oncocytic and 2 (5.4%) as unclassified types (Table II, Fig. 1 ). Intestinaland pancreatobiliary-type IPMNs showed a significantly increased histological grade compared to the gastric ones (P<0.001; Table II ). Branch duct-type IPMNs were more frequent in gastric type (47.7%) than other types (11.1%; P<0.05, data not shown). Gastric-type IPMNs (median diameter, 27.5 mm) were significantly smaller than intestinal (35 mm) and pancreatobiliary types (52.5 mm; P<0.05, data not shown).
Immunohistochemical expression of Cripto-1. Cripto-1 was stained diffusely in the cytoplasm. It was not expressed in acinar and ductal cells in the normal pancreatic specimens, but was weakly expressed in the cytoplasm of metaplastic duct cells in chronic pancreatitis. Of 37 IPMNs, 22 (59.5%) demonstrated a positive immunohistochemical expression of Cripto-1 (Table III) . According to the histological grade, 3 of 4 (75%) adenomas, 12 of 19 (63.2%) borderline neoplasms, 5 of 11 (45.5%) non-invasive carcinomas and 2 of 3 (66.7%) invasive carcinomas showed positive staining of Cripto-1. No correlation between the histological grade and Cripto-1 overexpression (P>0.05) was found. However, Cripto-1 overexpression differed among the subtypes (Fig. 2) 
Cripto-1 mRNA expression. For the quantitative analysis of
Cripto-1 mRNA expression, real-time RT-PCR was performed. Seven frozen specimens were used (2 adenomas, 2 borderline neoplasms, 1 carcinoma and 2 invasive carinomas). According to the phenotypic subclassification, 3 gastric, 2 intestinal and 2 pancreatobiliary-type specimens were used. Three normal pancreatic specimens from ampullary tumors were used to analyze the relative expression of Cripto-1.
The relative expression of Cripto-1 mRNA was elevated in IPMNs compared to normal pancreas (Fig. 3) . There was no correlation between histological progression and Cripto-1 mRNA expression. Cripto-1 mRNA was overexpressed in gastric-and pancreatobiliary-type IPMNs compared with the intestinal ones. The results of real-time RT-PCR analysis were consistent with those from immunohistochemical staining. Table I . Patient characteristics. Table II . Phenotypic subclassification and histological progression of IPMNs. - ---------------------------------------------------------------------------------------------------- 
-------------------------------------------------Variables No. of patients (%) -------------------------------------------------
) -------------------------------------------------
----------------------------------------------------------------------------------------------------- Histological progression n (%) --------------------------------------------------------- Carcinoma ------------------------- Adenoma Borderline Non-invasive Invasive Total P ----------------------------------------------------------------------------------------------------- Subtype <0.001 G 4 (21.1) 14 (73.7) 1 (5.3) 0 (0) 19 (51.4) I a 0 (0) 4 (40) 5 (50) 1 (10) 10 (27.0) PB a 0 (0) 0 (0) 4 (80) 1 (20) 5 (13.5) O 0 (0) 0 (0) 0 (0) 1 (100) 1 (2.70) U 0 1 (50) 1 (50) 0 (0) 2 (5.40) ----------------------------------------------------------------------------------------------------- G,
Discussion
Cripto-1 shows oncogenic properties as demonstrated by the in vitro cellular transformation of several mouse cell lines and in vivo mammary tumorigenesis in transgenic mice stably overexpressing a human Cripto-1 transgene in the mammary gland (10, 11, (22) (23) (24) . However, the precise function of Cripto-1 in carcinogenesis is not fully understood. Studies have demonstrated that Cripto-1 interacts with glypican-1, a membrane-associated heparin sulfate proteoglycan, and activates the cytoplasmic tyrosine kinase c-src (25, 26) , which triggers the ras/raf/mitogen-activated protein kinase (MAPK) pathway (27) and phosphatidylinositol 3'-kinase/Akt pathway (28) . In addition, Cripto-1 directly binds activin B and inhibits activin signaling, which acts as a potent tumor suppressor (30) . Several studies have also demonstrated that Cripto-1 may be involved in the early stages of carcinogenesis in different tissues. In MMTV/Cripto-1 transgenic mice, Cripto-1 overexpression induced mammary intraductal hyperplasia and papillary adenocarcinomas (23, 24) . Cripto-1 expression also significantly increases in several premalignant lesions, including gastric intestinal metaplasia, gastric and colon adenomas, and ductal carcinomas in situ of the breast (18, 30, 31) . In the present study, Cripto-1 expression significantly increased in adenomas and borderline neoplasms of the IPMN type, which means that Cripto-1 may be activated in an early stage of IPMN tumorigenesis.
A proposal made for the phenotypic subclassification of IPMNs was an effort to better understand the biological behavior of IPMNs and their clinical management (4). Our results, when utilizing the phenotypic subclassification, demonstrated that gastric types usually showed mild dysplasia and were frequently associated with branch duct types. Intestinal types showed moderate to severe dysplasia, whereas pancreatobiliary types showed severe dysplasia, which was consistent with a previous report (4) . The IPMN subtypes showed differential immunohistochemical staining of MUC, which implies diversity in the tumor progression pathway. The pancreatobiliary type shows a positive expression of MUC 1, which correlates with histological progression in invasive ductal adenocarcinoma (32) . MUC2 is expressed mainly in goblet cells of the intestine, which means intestinal differentiation is important in this subtype (33) (34) (35) . Our results show that Cripto-1 expression was significantly more frequent in gastric-and pancreatobiliary-type IPMNs compared with intestinal ones. These results support the possibility that the IPMN subtypes may have different carcinogenic pathways.
In conclusion, we demonstrated that Cripto-1 is overexpressed in the relatively early stages of IPMN progression and is significantly up-regulated in gastric-and pancreatobiliary-type IPMNs. Cripto-1 may be used as an early diagnostic marker of IPMNs, which have been studied in breast and colon cancer, and may be a new therapeutic molecular target of inhibiting the progression of IPMNs (36, 37) . ONCOLOGY REPORTS 21: 19-24, 2009 Table III. Cripto-1 expression according to histological progression and phenotypic subtype. ------------------------------------------------- 
